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The transcriptional activator PrfA, a member of the
Crp/Fnr family, controls the expression of some key
virulence factors necessary for infection by the hu-
man bacterial pathogen Listeria monocytogenes.
Phenotypic screening identified ring-fused 2-pyri-
done molecules that at low micromolar concentra-
tions attenuate L. monocytogenes cellular uptake
by reducing the expression of virulence genes. These
inhibitors bind the transcriptional regulator PrfA and
decrease its affinity for the consensus DNA-binding
site. Structural characterization of this interaction re-
vealed that one of the ring-fused 2-pyridones, com-
pound 1, binds at two separate sites on the protein:
one within a hydrophobic pocket or tunnel, located
between the C- and N-terminal domains of PrfA,
and the second in the vicinity of the DNA-binding he-
lix-turn-helix motif. At both sites the compound inter-
acts with residues important for PrfA activation and
helix-turn-helix formation. Ring-fused 2-pyridones
represent a new class of chemical probes for study-
ing virulence in L. monocytogenes.
INTRODUCTION
In light of increasing antibiotic resistance, novel therapies are
required to potentiate or succeed our current selection of thera-
peutic options (Davies and Davies, 2010). An alternative to
classical antibiotics are drugs inhibiting the virulence of patho-
genic bacteria. The first step in establishing this as a viable
and effective therapeutic strategy is to understand how the viru-
lence of pathogenic bacteria can be controlled (Allen et al., 2014;
Clatworthy et al., 2007; Rasko and Sperandio, 2010). The Gram-
positive bacterium Listeria monocytogenes is a saprophyte404 Cell Chemical Biology 23, 404–414, March 17, 2016 ª2016 The Aresponsible for the severe disease listeriosis in humans upon
ingestion (Freitag et al., 2009; Va´zquez-Boland et al., 2001). Its
ability to grow at low temperatures, in high-salt and low-oxygen
conditions, makes L. monocytogenes one of the most problem-
atic foodborne pathogens. Although the incidence rate is low,
L. monocytogenes is capable of crossing key protective barriers
within the body (e.g., intestinal, placental, and blood-brain) and
causing severe diseases (e.g., bacteremia, meningitis, and
meningoencephalitis) (Drevets and Bronze, 2008). Pregnant,
immunocompromised, and other at-risk patients are vulnerable
to invasive listeriosis, and the high mortality rates within these
subpopulations (20%–40%) are a stark demonstration of the
clinical difficulty in dealing with these infections (Drevets and
Bronze, 2008; Hamon et al., 2006; Jackson et al., 2010; Va´z-
quez-Boland et al., 2001).
The virulence factors governing host invasion and infection by
L. monocytogenes have been well elucidated (Va´zquez-Boland
et al., 2001). The bacterium adheres to and enters both phago-
cytic and non-phagocytic cells, by using specific adhesins
(e.g., InlA and InlB), depending on the cell type. With the aid of
listeriolysin O (LLO) and a phospholipase (PlcA), the bacterium
lyses the phagosome and proceeds to replicate intracellularly
(Schnupf and Portnoy, 2007). Once in the cytoplasm, the
bacterium uses the ActA protein to recruit the Arp2/3 complex
facilitating the formation of an actin comet-tail, by which
L. monocytogenes is able to move to an adjacent cell without
exposing itself to the extracellular environment. ActA has also
been shown to play a role during bacterial attachment and up-
take into epithelial cells (Garcia-Del Portillo and Pucciarelli,
2012; Suarez et al., 2001). Within the next cell, the bacterium de-
grades the double-membrane vacuole and perpetuates the
infection cycle (Hamon et al., 2006; Portnoy et al., 2002). The
expression of the majority of virulence genes required for these
processes is regulated by PrfA, a transcriptional activator from
the Crp/Fnr family of regulators (Scortti et al., 2007). Members
of this family bind as homodimers to consensus DNA sequences
found in the promoter region of regulated genes (Won et al.,
2009). PrfA positively regulates the expression of the aboveuthors
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et al., 2007), and a DprfA strain is avirulent (Andersson et al.,
2015; Chakraborty et al., 1992; Freitag et al., 1993; Gripenland
et al., 2014). Structurally, each monomer of PrfA comprises an
N-terminal eight-stranded b-barrel domain connected by an
a helix linker to a C-terminal a/b domain (Eiting et al., 2005;
Vega et al., 2004). The C-terminal region contains the winged he-
lix-turn-helix (HTH) motif responsible for binding to consensus
promoter sequences (Eiting et al., 2005; Vega et al., 2004). While
most Crp family members require a small molecule cofactor for
DNA binding (e.g., cAMP for Crp in Escherichia coli) (Won
et al., 2009), PrfA is capable of binding to its DNA consensus se-
quenceswith low affinity even in the absence of a cofactor (Eiting
et al., 2005). Nonetheless, the activity of PrfA is known to in-
crease under inducible conditions, and this has led to the hy-
pothesis that the intercellular mechanism of activation may be
regulated by a host-derived or host-regulated cofactor (Freitag
et al., 2009; Scortti et al., 2007). Recently, it was suggested
that PrfA activation follows a two-step process, where PrfA
needs to be in a reduced form for DNA binding, followed by inter-
action of PrfA with reduced glutathione for transcriptional activity
at targets genes (Reniere et al., 2015). Structural evidence to-
ward an allosteric mode of activation for PrfA in vivo has been
provided by the crystal structure of the constitutively active
PrfA mutant PrfAG145S (Eiting et al., 2005; Ripio et al., 1997;
Vega et al., 2004). This amino acid substitution repositions the
HTH motif in an ordered and exposed ‘‘active’’ conformation
with increased DNA-binding affinity, in contrast to PrfAWT where
the HTH motif remains flexible and partially disordered (Eiting
et al., 2005).
We previously developed ring-fused 2-pyridone scaffolds
which contain a peptidomimetic backbone (Svensson et al.,
2001). Originally designed to mimic interactions between sub-
units in the chaperone-usher pathway responsible for pilus as-
sembly in uropathogenic bacteria, we subsequently developed
inhibitors with discrete substitution patterns from this scaffold,
which both interact with structures important for E. coli adhesion
to eukaryotic cells (Cegelski et al., 2009; Emtena¨s et al., 2002;
Pinkner et al., 2006) and had broader impact on virulence
regulation (Greene et al., 2014). We were therefore interested to
investigate whether 2-pyridones could affect L. monocytogenes
virulence-associated phenotypes. In this study, we have con-
ducted a phenotypic screen and identified several ring-fused
2-pyridones that attenuate L.monocytogenes uptake into epithe-
lial cells and decrease virulence gene expression. We describe
how these inhibitors interact directlywith the transcriptional regu-
latorPrfA andweaken itsDNA-binding capacity. Furthermore,we
provide the first structural detail of a Crp family protein with a
bound inhibitor by presenting the crystal structure of PrfA in com-
plexwith one 2-pyridone, and propose possiblemodes of action.
RESULTS
Ring-Fused 2-Pyridones Attenuate L. monocytogenes
Uptake
Using flow cytometry, we performed an infection screen based
on HeLa cells infected with GFP-carrying L. monocytogenes.
The putative virulence-inhibiting ability of ring-fused 2-pyridones
from our in-house collection was assessed, and several closeCell Chemanalogs that significantly reduced the relative infection at
100 mM were identified (Figures S1A and S1B). At a concentra-
tion of 10 mM, two 1-naphthyl derivatives effectively reduced
L. monocytogenes uptake by HeLa cells by 80%–90% (C10 [1]
and KSK 67 [2]), whereas a related 3-quinoline analog, KSK 29
(3), was less effective (Figure S1B). Viable count experiments
verified these flow cytometry results, with compounds 1 or 2
reducing the level of L. monocytogenes uptake relative to
untreated controls at 10 and 1 mM (Figure 1A). Furthermore,
when we performed a time-course experiment monitoring the
infection dynamics more closely, we observed an inability of
L. monocytogenes to replicate within Caco-2 cells after treat-
ment with compound 2, which displayed the largest efficiency
in the uptake experiment (Figure 1B, left panel). Although the
generation time of L. monocytogeneswas slightly longer in pres-
ence of compounds 1 or 2 at 100 mM compared with the DMSO
control (45, 50, and 43 min, respectively), it is unlikely that this
would be sufficient to explain the dramatic decrease in infectivity
observed with these compounds at 100 mM and at lower con-
centrations (Figures S1C and 1). The generation time in the pres-
ence of compound 3 was unaffected compared with the DMSO
control (43 min, Figure S1C).
Ring-Fused 2-Pyridones Reduce Virulence Factor
Expression in L. monocytogenes
To understand how the compounds attenuated the infectivity
of L. monocytogenes, the expression of virulence genes was
analyzed in bacteria grown with or without 100 mM of 1, 2, or 3.
We initially investigated the expression of the hly gene which en-
codes the hemolysin LLO, and found it was downregulated by
1 or 2 compared with the untreated control, but not affected by
compound 3 (Figure S2). Together with most virulence genes
in L. monocytogenes, hly is positively regulated by the transcrip-
tional activator PrfA (Freitag et al., 2009; Scortti et al., 2007),
therefore we examined whether the expression of other PrfA-
regulated genes was affected by treatment with compounds
1 and 2. A reduction in the levels of the virulence genes hly,
actA, and plcA transcripts could be observed after treatment
with compounds 1 and 2 (but not 3), whereas the expression of
inlA and inlBwas unaffected (Figure S2), possibly because basal
expression of the latter are also controlled by other regulatory
factors, such as the stress sigma factor sB (Stritzker et al.,
2005). We next investigated whether the virulence protein levels
of the two major virulence factors, LLO and ActA, were affected
by compound treatment. Of the 2-pyridones tested, compounds
1 and 2 displayed similar properties. At 100 mMof 1 or 2, expres-
sion of LLO and ActA was abolished, without a concomitant
effect on PrfA protein levels or on the expression of the non-
PrfA-regulated virulence factor P60 (Figures 2A and 2B). The
reduction in LLO and ActA expression following treatment with
1 and 2 was dose dependent, with decreased levels down
to %3.3 mM (Figures 2A and 2B). In contrast, compound 3 did
not reduce LLO or ActA expression even at the highest concen-
tration tested of 100 mM, in agreement with the lack of efficacy
of 3 in abrogating hly or actA gene expression (Figures 2C
and S2). Across all concentrations of 1, 2, or 3, PrfA expression
remained unchanged, indicating that the virulence attenuation
of 1 and 2 was not mediated through reduced PrfA protein
levels (Figures 2A–2C). Once a host cell is invaded byical Biology 23, 404–414, March 17, 2016 ª2016 The Authors 405
AB
Figure 1. Ring-Fused 2-Pyridones Inhibit
L. monocytogenes Uptake by Cultured
Cells
(A) Relative uptake (%) compared with control as
determined by viable count measurements.
L. monocytogenes strain EGDe (WT) treated with
compounds 1–3 at the indicated concentrations
(10 mM, black bars; 1 mM, white bars) was al-
lowed to infect HeLa cells for 1.5 hr. All samples
were correlated to the DMSO control (C, gray
bar), which was arbitrarily set at 100%. Error
bars show SDs. Significance was tested using
Student’s t test (two-tailed, significant differ-
ences are shown by asterisks; *p < 0.05; **p <
0.01, and ***p < 0.001) and Dunnett’s test (sig-
nificant differences are shown by #). See also
Figure S1.
(B) Time-course infection dynamics of
L. monocytogenes harboring PrfAWT or PrfAG145S
after treatment with compound 2. Caco-2 cells
were infected with L. monocytogenes strains
carrying PrfAWT (left panels) or PrfAG145S (right
panels) on the chromosome in the presence
of DMSO (C) or compound 2 (50 mM). The amount
of intracellular bacteria was measured using
viable counts at indicated time points post
infection and divided by the bacterial load used in
the infection (prior to antibiotic treatment) arbi-
trarily set as % (n = 3). It should be noted that
infection of Caco-2 cells with a strain harboring
PrfAG145S is more effective than with a strain carrying PrfAWT. Error bars show SDs. Significance was tested using Student’s t test (two-tailed, significant dif-
ferences are shown by asterisks; *p < 0.05) and Dunnett’s test (significant differences to the control are shown by #).
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PrfA-dependent manner (Freitag et al., 2009; Scortti et al.,
2007). We therefore analyzed whether ActA expression was
affected at different time points when 100 mM of compound 2
was added 30 min post infection. The induction of intracellular
ActA levels observed in the DMSO control 4 hr post infection,
was weakened in compound-treated cells, although not
completely abolished (Figure 2D). This indicates that the effec-
tiveness of the compounds decreased post infection. We next
examined whether ring-fused 2-pyridones could also reduce
virulence factor expression in other L. monocytogenes strain
backgrounds or serotypes. Addition of compound 1 effectively
reduced LLO expression in L. monocytogenes serotypes associ-
ated with sporadic cases (10403S [serotype 1/2a] and LO28
[serotype 1/2c]) as well as a serotype associated with epidemic
outbreaks (F2365 [serotype 4b]), whereas the levels of PrfA were
unaffected in these strains (Figure 3A). In addition, compound 2
effectively inhibited uptake of the F2365 strain into Caco-2 cells
(Figure 3B).
Virulence Regulation by the Mutant PrfAG145S Is Not
Affected by Ring-Fused 2-Pyridones
The reduced levels of the virulence factors LLO and ActA, but
not of PrfA (Figures 2A and 2B), suggested that 1 and 2 directly
affected the activity of PrfA. Introducing a G145S amino acid
substitution in PrfA generates a constitutively active mutant
that contains a stabilized HTH DNA-binding motif, as opposed
to the structurally undefined HTH present in PrfAWT (Eiting
et al., 2005; Ripio et al., 1997). Examining the effect of the com-
pounds on PrfAG145S in comparison with PrfAWT would indicate406 Cell Chemical Biology 23, 404–414, March 17, 2016 ª2016 The Awhether 1 and 2 directly inhibited the PrfA activation process,
or if their effects were mediated after formation of the HTH
DNA-binding motif. To test this, a prfAG145S allele was intro-
duced at its native site on the chromosome, such that
PrfAG145S would be produced, and this strain was treated
with 1, 2, or 3 at 100 mM. In the PrfAG145S-expressing strain,
virulence gene expression as well as virulence protein levels re-
mained essentially unaltered in the presence of the compounds
(Figures 4 and S2). Once again, the levels of PrfA and P60
proteins did not vary considerably after treatment with the
different compounds. We next challenged whether this muta-
tion could also overcome the inhibitory effects of these com-
pounds in a time-course cellular infection assay, with the
most effective compound from the cellular uptake experiments,
compound 2. While L. monocytogenes containing PrfAWT was
unable to replicate within Caco-2 cells in presence of 2 at
100 mM (Figure 1B, left panel), a strain expressing PrfAG145S
overcame the inhibitory effects and established an infection
comparable with the untreated control (Figure 1B, right panel).
Collectively, these data strongly indicated that the 2-pyridones
1 and 2 reduced L. monocytogenes virulence by attenuating
PrfA activity, and furthermore suggested that this process
occurred prior to formation of the DNA-binding HTH motif,
since the PrfAG145S protein carrying the stabilized HTH motif
was not affected by the compounds.
Ring-Fused 2-Pyridones Directly Bind to PrfA In Vitro
We next determined whether 1 and 2 directly bound to PrfA via
isothermal titration calorimetry (ITC). This in vitro method, with
purified PrfA protein, allowsmeasurement of the thermodynamicuthors
DC
B
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Figure 2. Compounds 1 and 2 Reduce Virulence Factor Expression
in L. monocytogenes
(A–C) Protein extracts were isolated from indicated L. monocytogenes strain in
the absence (C, equivalent volume of DMSO) or presence of 1 (A), 2 (B), or 3 (C)
at the indicated concentration, and the specified proteins (ActA, LLO, PrfA, or
P60 (control)) were detected by western blot using specific antibodies. Upper
panels show secreted fractions (Sup) of indicated samples; lower panels show
whole cells fractions (WC) of indicated samples. The images are a represen-
tative of three individual experiments. (D) Compound 2 abrogates intracellular
induction of ActA expression. Caco-2 cells were infected with the indicated
bacteria and treated 30 min post infection with 100 mM of 2 or the equivalent
B
A
Figure 3. Compounds 1 and 2 Reduce Virulence Factor Expression
and Uptake of Multiple Serotypes of L. monocytogenes
(A) Compound 1 reduces LLO expression in different L. monocytogenes strain
backgrounds. Protein extracts were isolated from indicated L.monocytogenes
strain in the absence (C, equivalent volume DMSO) or presence of 100 mMof 1
and the specified proteins (LLO PrfA, or P60 (control)) were detected by
western blot using specific antibodies. Upper panels show secreted fractions
(Sup) of indicated samples; lower panels show whole-cell fractions (WC) of
indicated samples.
(B) Compound 2 inhibits the uptake of an L. monocytogenes strain of serovar
4b. L. monocytogenes strain F2365 was allowed to infect Caco-2 cells for 2 hr
with 2 (50 mM). All samples were correlated to the DMSO-treated control
(C, gray bar) which was arbitrarily set at 100%. Error bars show SDs. Signifi-
cance was tested using Student’s t test (two-tailed, significant differences are
shown by asterisks; ***p < 0.001) and Dunnett’s test (significant differences to
the control were shown by #).
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(2016), http://dx.doi.org/10.1016/j.chembiol.2016.02.013parameters of binding from the heat development that occurs
upon ligand-protein interactions (Ladbury et al., 2010). The
data presented in Figure 5A show that binding of 1 to PrfAWT
occurs with negative enthalpy in a 1 to 1 stoichiometry permono-
mer of homodimeric PrfA. From analysis of the integrated heat
peaks as a function of ligand-to-protein ratio using a 1 to 1 bind-
ingmodel, a dissociation constant (KD) value for 1 binding to PrfA
of z1 mM was determined (Table 1). Compound 2, and unex-
pectedly 3, also exhibited micromolar affinities for PrfAWT and in-
teracted in 1 to 1 stoichiometry (Table 1 and Figure S3). We
examined the binding of compounds 1–3 to the constitutively
active PrfA mutant PrfAG145S and found that all three ligands
bound to PrfAG145S with comparable affinity for 2 and reduced
affinity for 1 and 3 (Table 1). These data suggested that thevolume of DMSO (C). Total cellular protein was extracted at indicated time
points after addition of compound and subjected to SDS-PAGE. The levels of
ActA protein were visualized by western blot using a specific antibody. The
images are a representative of three individual experiments.
ical Biology 23, 404–414, March 17, 2016 ª2016 The Authors 407
Figure 4. Compounds 1, 2, and 3 Cannot Inhibit LLO and ActA
Expression in a Strain Expressing a Constitutively active PrfA Pro-
tein PrfAG145S
The indicated strains were grown with 1–3 at 100 mM or DMSO (C). Upper
panels show secreted fractions (Sup) of indicated samples; lower panels show
whole-cell fractions (WC) of indicated samples. The levels of LLO, ActA, PrfA,
and P60 (control) proteins are visualized by western blot using specific anti-
bodies. The images are a representative of three individual experiments. See
also Figure S2.
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region differs in conformation between the mutant (folded)
versus the wild-type (WT) (partially disordered) (Eiting et al.,
2005).
Compounds 1 and 2 Inhibit the DNA Binding of PrfAWT,
but Not PrfAG145S
To further characterize the binding of 1–3 with PrfA in vitro, and
analyze if such binding affects the DNA-binding properties of
PrfA, we performed surface plasmon resonance (SPR) experi-
ments. In these in vitro experiments, the ability of PrfA (WT or
G145S), pre-incubated with 1–3, to bind the hly-promoter DNA
was analyzed. Compounds 1 and 2, which reduced infectivity
and the expression of key virulence factors in the cellular assays,
both effectively reduced the binding of PrfAWT to hly-DNA at low
micromolar levels via SPR (half maximal inhibitory concentration
[IC50] z 6–7 mM; Figure 5B). The quinolone-containing com-
pound 3, which had only a slight effect in the cellular assays
and did not attenuate virulence factor expression, could only
inhibit the binding of PrfAWT to hly-DNA at higher concentrations
(IC50z 30 mM), indicating it was less effective at preventing the
PrfA-hly interaction (Figure 5B). Furthermore, all the compounds
had minimal impact upon the binding of PrfAG145S to hly-DNA at
concentrations up to 100 mM (Figure 5C). Taken together,
we conclude that while 1–3 bind to the constitutively active
mutant PrfAG145S, this has no significant impact on its ability to
bind DNA.
Crystal Structure of PrfAWT-1 Complex
To understand the structural basis for inhibition, we determined
the crystal structure of the PrfAWT-1 complex at a resolution of
2.25 A˚ (Table 2). The PrfAWT-1 complex was co-crystallized in
the space group P21 where the asymmetric unit contains one408 Cell Chemical Biology 23, 404–414, March 17, 2016 ª2016 The Abiological dimer: monomers A and B (Figure 6A). Binding of 1
to PrfAWT was confirmed at two sites, AI in monomer A and BII
in monomer B, from difference Fourier electron density maps
(Figures 6B, 6C, and S4).
The PrfAWT-1 dimer structure is similar to the previously
determined structures of PrfAWT (Eiting et al., 2005) (Figures
6A and S5). Each monomer consists of an N-terminal domain
(residues 1–108) and a C-terminal DNA-binding domain (resi-
dues 138–237) linked by a long a helix (aC, residues 109–
137). Both the N- and C-terminal domains constitute an a/b
fold. Hydrophobic interactions between symmetry-related aC
helices and loops b6-b7 stabilize the dimer interface (Figure 6A).
Two a helices in the C-terminal domain, aE (residues 170–178)
and aF (residues 183–195) constitute the helices of the typical
HTH motif present in many prokaryotic transcription factors. In
PrfAWT, parts of the first helix and the connecting turn of the
PrfA HTH motif were not defined by electron density and
have been assumed to be flexible (Eiting et al., 2005). This
was also the case for the PrfAWT-1 complex structure deter-
mined here.
Compound 1 binds PrfA at two sites referred to as AI and BII.
Site AI is found at the so-called interdomain tunnel in monomer
A, situated between the N- and C-terminal domains (Figure 6B).
The interdomain tunnel is positioned between the C-terminal
helices aH and aI and the secondary structural motifs aC,
aD, and b5 (Eiting et al., 2005). Compound 1 binds with high
occupancy at site AI, but no ligand bound to the tunnel in
monomer B (i.e., to the BI site). At binding site AI the carbox-
ylate is in close proximity with the charged 3-amino groups of
Lys64 and Lys122, indicating the potential for both electrostatic
interactions and a network of hydrogen bonding, which in the
case of Lys122 are mediated through the bulk solvent (Fig-
ure 6D). The naphthyl ring occupies a hydrophobic part of the
tunnel bounded by the peptide backbones of Tyr62, Gln146,
Ile149, and Leu150, and the cyclopropyl motif is surrounded
between the peptide backbone of Gln123 and the phenyl rings
of Tyr63, Phe67, and Tyr126, respectively. We reason that the
peptidomimetic bicyclic 2-pyridone backbone provides the
key recognition motif for binding to PrfA at the AI site, with
the carboxylate forming electrostatic interactions with residues
known to affect the activation of PrfA (Lys64 and Lys122)
(Xayarath et al., 2011), and the naphthyl motif providing a lipo-
philic anchor into the interdomain tunnel. The second high-oc-
cupancy binding site for compound 1, i.e., the BII site, is found
at a hydrophobic pocket in the vicinity of the HTH motif in
monomer B (Figure 6C). No ligand bound to the corresponding
site in monomer A (i.e., to the AII site). The BII site is positioned
in a pocket formed by the aC and aD helices and b5 strand
from monomer B and the C-terminal end of the aC helix from
monomer A (Figure 6C). At site BII, the carboxylate group of
compound 1 forms hydrogen bonds to the main chain nitrogen
atom of B-Tyr62, and to the hydroxyl group of B-Tyr126 and
the 2-pyridone carbonyl hydrogen bonds with the side chain
amino group B-Gln61. The naphthyl group of compound 1 at
site BII is sandwiched between the side chains of four phenyl-
alanines: Phe131 and Phe134 from both monomers in the
dimer (Figure 6E). The charged lysine of B-130 is also suffi-
ciently close (4.8 A˚) for electrostatic interactions with the
carboxylate group to affect the free energy of binding.uthors
A B
C
Figure 5. Ring-Fused 2-Pyridones Bind to
PrfA and Decrease the Affinity of PrfAWT,
but Not PrfAG145S, for hly-DNA
(A) ITC titration of 1 to PrfAWT. Upper panel, heat
pulses versus injections; lower panel, integrated
heat signals versus molar ratio of 1 to PrfAWT.
(B) and (C) SPR plots of relative binding affinity of
PrfAWT and PrfAG145S with 1–3 to hly-DNA. PrfAWT
(B) or PrfAG145S (C) was incubated with the indi-
cated amounts of 1, 2, or 3. The samples were
analyzed by SPR and the relative binding capacity
plotted. All compounds were compared with
DMSO, which was set to 100% (n = 3). Data rep-
resents the mean values with SDs.
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In this work, we identified ring-fused 2-pyridone inhibitors
by phenotypic screening which effectively attenuated
L. monocytogenes uptake into cultured cells at low micromolar
concentrations. Compounds 1 and 2, which were investigated
in most detail, exhibited similar reductions in virulence and infec-
tivity across all assays. A structurally discrete third analog, 3,
consistently failed to attenuate uptake although still binding
PrfA in vitro, which may be attributable to lower intrinsic efficacy
(Figure 5B) and less optimal physicochemical properties than
1 and 2. Collectively, the results indicate that 1 and 2 act by bind-
ing to and preventing the activation of PrfA, the central transcrip-
tional regulator of virulence in L. monocytogenes. The ring-fused
2-pyridone molecules bind to purified PrfA with KD values in the
low micromolar range (Table 1 and Figure 5). Consequently, this
lowers the affinity of the protein for its DNA consensus se-
quences within the promoter regions of virulence genes (Fig-
ure 5B). This reduced DNA-binding affinity in turn abolishes the
expression of key virulence factors, which reduces uptake in
epithelial cells (Figures 1, 2, and 3; Figures S1 and S2).
Our functional and structural studies support a model where 1
and related inhibitors act either by preventing the structural rear-
rangements needed for activation of PrfA through stabilization of
the HTH motif, or alternatively by preventing the concerted reor-
ganization of the monomers that move the DNA-binding do-
mains into positions compatible with DNA binding (Levy et al.,
2008; Schultz et al., 1991). Previous structural studies on PrfA
and the constitutively active PrfAG145S mutant revealed that rear-
rangements at the dimer interface enable the stabilization of the
HTH motif in PrfAG145S into a structurally defined conformation
with increased affinity to DNA (Eiting et al., 2005). Comparison
between the two structures suggested that for DNA binding to
occur, helix aC needs to straighten leading to rearrangements
of b4-b5. Phe134, positioned on aC, flips over to fill the void
created between helices aC and aD. Furthermore, Tyr62 posi-
tioned at b5 moves to fill the same void and to bring the side
chains of Ile57 and Asn59 into direct contact with the now struc-
turally defined first helix in the HTH motif (Eiting et al., 2005).
Compound 1 binds to site AI, a hydrophobic interdomain tunnelCell Chemical Biology 23, 404–41previously suggested to constitute a
plausible cofactor binding site (Eiting
et al., 2005) and to site BII, a hydrophobic
pocket in the vicinity of the HTH motif(Figures 6, S6A, and S6B). We reason that inhibitor binding at
AI could prevent conformational changes of the PrfA protein,
and thus block the inducible activation of PrfA. In support, the
structural data demonstrate electrostatic interactions between
residues Lys64 and Lys122 with the carboxylate moiety of inhib-
itor 1, and van der Waal contacts between the aliphatic back-
bone of Tyr62 and the naphthyl ring of 1 (Figure 6D). Both
Lys64 and Lys122 have previously been implicated as being
involved in PrfA activity: K64Q or K122Q mutants exhibited
reduced ActA expression, weakened capability to bind hly-
DNA, and attenuated virulence (Xayarath et al., 2011). At site
BII compound 1 binds in the vicinity of the flexible HTHmotif (Fig-
ures S6B and S6C). At this site the naphthyl group of compound
1 sterically prevents restructuring of residues Phe131 and
Phe134 into positions needed for formation of an HTH motif
compatible with DNA binding (Figure S6D) (Levy et al., 2008;
Schultz et al., 1991). One interesting observation from the
in vitro experiments was the binding of 1–3 to both PrfAWT and
PrfAG145S determined by ITC, despite the lack of efficacy against
strains harboring the constitutively active G145S mutant (Ta-
ble 1). Since the PrfAG145S mutant that has structurally defined
HTH motifs can still bind to its consensus DNA when in complex
with 1 (Figure 5C), one possibility is that compound 1 only binds
at the AI site in the PrfAG145S mutant. Binding of 1 in the tunnel
only of PrfAG145S needs, however, to be structurally verified in
future, and the similar binding efficacies of 1–3 in vitro suggest
that additional complexities may emerge in the in vivo mecha-
nism of PrfA inhibition.
It has previously been shown that ActA is important for bacte-
rial uptake into epithelial cells including Caco-2 and Hela (Suarez
et al., 2001). ActA has also been suggested to promote the initial
contact between the bacteria and the cell by binding Heparan
sulfate proteoglycan receptor, thereby allowing a stable contact
between InlA or InlB with E-cadherin and Met, respectively (Gar-
cia-Del Portillo and Pucciarelli, 2012). Thus, our results showing
a decreased uptake of bacteria in the presence of compounds
1 and 2 is consistent with a reduced expression of ActA (Figures
1 and 2). Furthermore, while compounds 1 and 2 were effective
at attenuating virulence when added prior to infection, only high
concentrations of 2 reduced ActA expression post infection4, March 17, 2016 ª2016 The Authors 409
Table 1. Binding Parameters of 1–3 to PrfAWT and PrfAG145S as
Determined by ITC
Protein Compound KD (M)
DHA
(kcal/mol)
DSA
(cal/mol$K)
PrfAWT 1 1.0 (±0.2) 3 10
6 8.4 ± 0.1 0.8 ± 0.1
2 6.7 3 106 6.5 2.8
3 1.6 (±0.2) 3 106 8.4 ± 0.2 1.5 ± 0.9
PrfAG145S 1 7.75 3 10
6 6.2 2.6
2 5.4 3 106 4.1 10.4
3 5.0 (±1.8) 3 106 6.2 ± 1.0 3.4 ± 4.1
DHA, enthalpy of association and DSA, entropy of association. Deter-
mined at 293 K. In all cases, 1 to 1 stoichiometry per PrfA monomer
was observed. Errors refer to independent repetitions (2–3) of experi-
ments. Fitting errors not shown. See also Figures 5 and S3.
Table 2. Data Collection and Refinement Statistics
PrfAWT-1
Data Collection
Space group P21
Cell dimensions
a, b, c (A˚) 56.34, 80.97, 62.34
a, b, g () 90.00, 112.54, 90.00
Resolution (A˚) 57.58–2.25 (2.33–2.25)a
Rmerge 0.058 (0.985)
Rpim 0.041 (0.698)
Wilson B factor (A˚2) 60.3
<I/sI> 12.1 (1.6)
Completeness (%) 99.2 (97.9)
Redundancy 5.6 (5.5)
CC1/2b 2.25 A˚
Refinement
Resolution (A˚) 57.58–2.25 (2.33–2.25)
Number of reflections 24,400 (2,375)
Rwork/Rfree 0.203/0.254 (0.370/0.400)
Number of atoms
Protein 3,738
Ligand 54
Water 22
B factors (A˚2)
Protein
Monomer A 86.6
Monomer B 83.6
Ligands
1 (AI) 65.5
1 (BII) 70.1
Water 61.2
Root-mean-square deviation
Bond lengths (A˚) 0.016
Bond angles () 1.40
Ramachandran (%)
Favored 98.0
Outliers 0.0
Clash score 3.21
aData collected from one crystal.
bSuggested resolution cut-off (AIMLESS, see Supplemental Experi-
mental Procedures). Values in parentheses are for highest-resolution
shell.
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bility of the compounds for PrfA after bacterial internalization
or increased compound turn-over may have contributed to
this, or the compounds may act more effectively at the step prior
to PrfA activation (Figure 2D). The mechanism of intracellular
PrfA activation has been postulated to involve a small molecule
cofactor (Deshayes et al., 2012) that induces the ordering of
the HTH motif evident in the PrfAG145S structure, thus enabling
high-affinity interactions with consensus DNA sequences (Eiting
et al., 2005). Recently it was shown that PrfA is more capable of
initiating virulence gene expression if it is in a reduced state and
bound to reduced glutathione (Reniere et al., 2015). Post infec-
tion, the inhibitory compounds are likely in competition with a
cofactor, and PrfA activation may already have occurred, giving
rise to a stable HTH motif. Consistent with this scenario is the
reduced efficacy of compounds post infection (Figure 2D) and
loss of efficacy against strains bearing the constitutively active
PrfAG145S (Figure 4). In addition, both PrfAWT- and PrfAG145S-ex-
pressing strains were able to replicate efficiently in J774.1
macrophage-like cells after treatment with 2 (Figure S7), in line
with the finding that maximal PrfA activity is not required for
L. monocytogenes replication in bone marrow-derived macro-
phages (Reniere et al., 2015). Although our body of evidence
clearly shows that the 2-pyridones interact with and inactivate
PrfA, we do not completely rule out the possibility that they
might also affect additional components contributing to
L. monocytogenes virulence.
Other Crp/Fnr family members, such as Crp in E. coli, utilize
cAMP binding for activation (Won et al., 2009). While the cAMP-
binding site is topologically conserved within the N-terminal
domain of PrfA, the residues involved in cAMP binding are
not (Eiting et al., 2005). The crystal structure of the PrfAWT-1
complex shows that 1 does not bind at the conserved Crp
cAMP-binding site (Figure S5B), nor to a solvent accessible
cavity in the N-terminus of PrfA, recently proposed as a poten-
tial cofactor binding site (Deshayes et al., 2012). The described
inhibitors are therefore unlikely to compete with a cofactor
binding at those sites. The interdomain tunnel where 1 binds
at site AI has previously been proposed as a possible effector
site (Eiting et al., 2005), and our findings provide additional sup-
port for the importance of this region within an allosteric model
of activation for PrfA. Further studies can clarify the relationship410 Cell Chemical Biology 23, 404–414, March 17, 2016 ª2016 The Abetween glutathione as a substrate for activation and the
discovered inhibitors.
Compound 1 came from a collection of molecules designed to
block pilus assembly in E. coli through disrupting the chaperone-
usher pathway (Emtena¨s et al., 2002; Svensson et al., 2001).
When used at a concentration of 3.6mM, 1 blocked pilus biogen-
esis in E. coli, which raises the question of whether such effects
may have beenmediated through inhibition of Crp (Pinkner et al.,
2006). The broad applicability of compounds based on 1 and 2 to
inhibit other Crp/Fnr family members requires further investiga-
tion; however, several factors point against the favorability ofuthors
Figure 6. Structureof thePrfAWT-1Complex
(A) The PrfAWT homodimer showing the binding
site of 1. The monomeric units A and B of PrfAWT
are colored in blue and gold, respectively. Two li-
gands bound to each monomer at two different
sites, are shown as sticks.
(B and C) Quality of the electron density for
compound 1 bound (A) to monomer A (site AI)
and (C) to monomer B (site BII). The sA-weighted
(2mjFoj  DjFcj) electron density calculated from
the refined PrfA-1 complex is contoured at the
root-mean-square deviation value of the map and
shown in blue over compound 1 only.
(D) and (E) Key local structural features and
amino acids in proximity to 1 at site AI (D)
and BII (E). The ligand is colored by atom
type: purple (C), green (S), blue (N), and red
(O) and protein residues are colored by atom
type: monomer A (C) yellow and monomer B
(C) orange, green (S), blue (N), and red (O).
Hydrogen bonds are indicated with dashed
lines.
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inhibitors. At concentrations much higher than applied here,
1 had no effect in E. coli on the Crp-regulated pili expression
(at 800 mM) (Cegelski et al., 2009; Chorell et al., 2010). At the pro-
tein level, PrfA differs structurally from Crp by the presence of
three extra C-terminal helices (aG-aI) at the AI site (Eiting et al.,
2005) and the BII site with its HTH motif is too compact to allow
binding of 1 in Crp. Finally, at the bacterial level, the Gram-nega-
tive pathogen E. coli and Gram-positive L. monocytogenes are
topologically distinct, which can have a profound impact on up-
take and accessibility for small molecule inhibitors. The present
work, however, provides a compelling proof-of-concept for
investigating small molecule inhibitors of Crp family members
as a means to disrupt the virulence of pathogenic bacteria.
Antivirulence drugs could provide a powerful, and potentially
complementary treatment option to conventional antibiotics. In-
hibitors of virulence in pathogenic bacteria, rather than inhibitorsCell Chemical Biology 23, 404–41of viability, are now emerging, but only a
few examples have been reported where
the key regulator of virulence has been
directly inactivated and none have
provided structural details of the regu-
lator-compound interaction (Garrity-
Ryan et al., 2010; Hung et al., 2005;
Shakhnovich et al., 2007; Sun et al.,
2011; Yang et al., 2013). In the present
work, we have identified a class of ring-
fused 2-pyridones which attenuate
L. monocytogenes virulence through in-
hibiting PrfA activation. These inhibitors
represent excellent tool compounds for
studying the virulence of this potentially
fatal pathogen. Furthermore, the eluci-
dated crystal structure of PrfA in complex
with compound 1 enables improved
ligand design, and provides a compelling
rationale for the further investigation ofCrp family members with small molecule inhibitors. Translating
this research into a clinical application requiresmore effective in-
hibitors and in vivo proof-of-concept, but these findings repre-
sent the first steps in this process of identifying new therapeutic
opportunities to treat infectious diseases.
SIGNIFICANCE
With increasing antibiotic resistance, new therapeutic
strategies are needed to control bacterial infections, and
virulence inhibition may afford opportunities for effective
control. In this article, we have identified ring-fused 2-pyri-
dones that attenuate the virulence of the Gram-positive
bacterial pathogen Listeria monocytogenes by decreasing
expression of central virulence genes. We identify the viru-
lence regulator PrfA as the target of the compounds, and
show how these inhibitors interact directly with PrfA to4, March 17, 2016 ª2016 The Authors 411
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(2016), http://dx.doi.org/10.1016/j.chembiol.2016.02.013reduce its DNA-binding capacity. The identified inhibitors
are a new set of tool compounds for improving our under-
standing of L.monocytogenes virulence.Wepresent the first
crystal structure of a Crp/Fnr familymember in complexwith
an inhibitor, and this affords new opportunities for designing
ligands targeting this widespread family of bacterial tran-
scriptional regulators.
EXPERIMENTAL PROCEDURES
Chemistry
All tested compounds were ofR95% purity as determined by liquid chroma-
tography-mass spectrometry. Compound 1 was synthesized as described
previously (Chorell et al., 2010). Compounds 2–5 were synthesized by Su-
zuki-Miyaura cross-coupling with the chloromethyl ester 6 and subsequently
hydrolyzed (Figure S8) (Chorell et al., 2010; Sellstedt et al., 2012). Detailed pro-
cedures and characterization are provided in the Supplemental Experimental
Procedures.
Cell Lines, Bacterial Strains, and Growth Conditions
L. monocytogenes strains (EGDe, Mackaness, 1964; EGDe DactA, Tiensuu
et al., 2013; EGDe DprfA, Toledo-Arana et al., 2009; EGDe Dhly, Tiensuu
et al., 2013; LO28, Vicente et al., 1989; 10403S, Myers et al., 1993; and
F2365, Nelson et al., 2004) were grown in brain heart infusion (BHI) medium
(Fluka) at 37C with aeration (180 rpm), unless otherwise stated. For growth
rate determination, samples were withdrawn every 30 min and optical density
at 600 nm (OD600) was measured. When required, erythromycin was used at a
final concentration of 10 mg/ml. E. coli (DH5a; Bethesda Research Labora-
tories, 1986) was grown in Luria-Bertani medium at 37Cwith agitation, unless
otherwise stated. Antibiotics were, where appropriate, supplemented to final
concentrations of 34 mg/ml for chloramphenicol and 100 mg/ml for kanamycin.
HeLa cells were maintained in RPMI 1640 medium, whereas Caco-2 and J774
cells were maintained in DMEM, both supplemented with GlutaMAX Supple-
ment (Gibco, Life Technologies) and 10% fetal bovine serum (Gibco, Life Tech-
nologies) at 37C in a 5% CO2 atmosphere.
Infection
L. monocytogenes EGDe, grown to anOD600 of 1.0, was pelleted, washed, and
diluted in RPMI. DMSO or compound dissolved in DMSO was then added to
the bacteria, resulting in a final concentration of 0.5% DMSO (v/v). The bacte-
rial suspensions were added to the mammalian cells at a multiplicity of infec-
tion of approximately 10 and incubated for 1 hr at 37C, before the cells were
washed in PBS and incubated for 1.5 hr in cell medium supplemented with
50 mg/ml gentamycin. The cells were washed in PBS and subsequently lysed
with PBS supplementedwith 1%Triton X-100. The amount of intracellular bac-
teria was quantified by viable count of the cell lysate. For flow cytometry: after
infection as above, the cells were washed in PBS and incubated for 7 hr in
RPMI supplementedwith 50 mg/ml gentamycin and subsequently analyzed us-
ing the Guava easyCyte (Millipore) flow cytometer. For intracellular protein
levels, see Supplemental Experimental Procedures.
Western Blot
Overnight cultures of L. monocytogenes were diluted to an OD600 of 0.025 in
BHI supplemented with DMSO, or the compounds dissolved in DMSO, result-
ing in a final concentration of 0.1% DMSO (v/v). The cultures were grown at
37C to an OD600 of 1.0 before centrifugation (4,500 rpm, 10 min, 4C). The su-
pernatants and bacterial pellets were collected and subjected to SDS-PAGE
and western blotting using specific antibodies. A detailed procedure is pro-
vided in the Supplemental Experimental Procedures.
Surface Plasmon Resonance
SPR experiments was conducted in a Biacore X100 (GE Healthcare), and
performedmainly as described previously (Deshayes et al., 2012). In brief, bio-
tinylated oligonucleotides (Promo40plcA-P14/Promo40plcAREV) containing
the PrfA box of the plcA promoter were immobilized on one flow cell of an
SA Chip (GE Healthcare). Assays were performed at 37C. Protein samples
were diluted in HBS-EP+ (GE Healthcare) to a final concentration of 200 nM,412 Cell Chemical Biology 23, 404–414, March 17, 2016 ª2016 The Aand compounds at different concentrations were added, resulting in a final
DMSO concentration of 0.5%. The samples were injected with a flow rate of
10 ml/min. HBS-EP+ was used as running buffer. Measurements were done
with a contact time of 200 s and a dissociation time of 120 s. This was followed
by regeneration solution (0.1% SDS, 3 mM EDTA) with a contact time of 60 s.
A flow cell without any immobilized DNA was used for reference subtraction.
Each run was repeated three times.
Isothermal Titration Calorimetry
ITC experiments were performed using a MicroCal AutoiTC200 (GE Health-
care). In a typical run, 25 automated injections of 1.65 ml with 170-s breaks
between injections were made at 25C with 600 rpm stirring speed on low
feedback mode. The protein concentrations in the sample cell were varied be-
tween 25 and 100 mM, while the compound concentration in the syringe was
varied from 300 to 800 mM. The buffer for both protein and compound solutions
was the same as in the final step of the purification. The compounds were
dissolved in DMSO, and then diluted with buffer. DMSO content in the final
compound solutions did not exceed 0.5% (v/v). Data integration, fitting, and
evaluation were performed using the software Origin 7 with the ITC200 plugin
provided by MicroCal/GE Healthcare.
Protein:Compound Crystallization and Data Collection
PrfA in complex with 1 was co-crystallized by the hanging-drop vapor-diffu-
sion technique at 18C. Crystals (0.1 3 0.4 3 0.02 mm3) grew in 5 days
when the protein solution (3.5 mg/ml PrfA, 0.75 mM 1, 200 mM sodium chlo-
ride, 20 mM NaP [pH 6.5]) was mixed with an equal volume of mother liquor
containing 20% PEG-4000, 16% isopropanol, and 100 mM sodium citrate
(pH 5.5). Before data collection, the crystals were transferred to a cryo-protec-
tant solution including 16% (v/v) glycerol in the precipitant solution. The
crystals were flash-cooled to 100 K using a Cryostream 700 cooler (Oxford
Cryosystems) and stored in liquid nitrogen. Diffraction data were collected at
100 K at the ESRF beamline ID29 (X-ray wavelength = 0.914 A˚). The structure
was solved with molecular-replacement methods. Data collection and refine-
ment statistics are shown in Table 2. Details of the structure determination are
provided in the Supplemental Information. The atomic coordinates and struc-
ture factors have been deposited (PDB: 5F1R) in the Research Collaboratory
for Structural Bioinformatics (RCSB), Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
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